Recent work has evaluated the use of chemotherapeutic agents to sensitize TRAIL-resistant cells by mediating the apoptotic effect of recombinant TRAIL, resulting in the proposal that chemotherapeutic agents, such as paclitaxel, could be used as a pre-treatment for sensitizing CD133+ (CSC marker) to the effect mediated by TRAILs by reducing the expression of the antiapoptotic genes cFLIP and Bcl-XL in pancreatic cancer [106]. The gene discussed is TNFSF10; the disease is pancreatic neoplasm.